Theravance Reports Positive Phase II Results For Chronic Constipation Therapy TD-5108
This article was originally published in The Pink Sheet Daily
Executive Summary
Specificity of the 5-HT4 agonist gives it a better cardiovascular safety profile than withdrawn Novartis product Zelnorm, Theravance VP-Development Kitt says.
You may also be interested in...
GlaxoSmithKline Declines To License Theravance GI Motility Drug At Brink Of Phase III
Astellas deals Theravance a second blow by opting out on late-stage antibiotic candidate TD-1792, which could eventually compete with telavancin.
GlaxoSmithKline Declines To License Theravance GI Motility Drug At Brink Of Phase III
Astellas deals Theravance a second blow by opting out on late-stage antibiotic candidate TD-1792, which could eventually compete with telavancin.
Zelnorm Will Be Available Under Treatment IND Following Marketing Suspension
Novartis voluntarily suspends marketing of the irritable bowel syndrome medication due to cardiovascular events.